Description
LHC-165 is a benzonaphthyridine TLR7 agonist.
| Product Unit Size | Cost | Quantity | Stock |
|---|
LHC-165 is a benzonaphthyridine TLR7 agonist.
| Cas No. | 1258595-14-0 |
|---|---|
| Purity | ≥99% |
| Formula | C29H32F2N3O7P |
| Formula Wt. | 603.56 |
| IUPAC Name | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
| Synonym | LHC165 |
| Appearance | Pale yellow powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Zawit M, Swami U, Awada H, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. PMID: 34277838
Modifies microvascular function
Peptide, involved in feeding behavior and insul...
Valsartan impurity
Aza-anthracenedione, DNA intercalator; topoisom...
Endogenous tachykinin peptide, involved in infl...
Quinoline, food preservative; HSP90 inhibitor.<...
PKA substrate.
Potential anxiolytic.
V600E B-Raf inhibitor.
PDEδ inhibitor.
Synthetic antioxidant that induces phase II enz...
Flavanol originally found in Camilla (green tea...
TLR4 inhibitor.
Laminin-derived nonapeptide.
Aminopeptidase inhibitor.
Fluoroquinolone; topoisomerase IV and bacterial...
Cholesterol ester transfer protein inhibitor.
Steroidal alkaloid found in Fritillaria; TRPV1 ...
ITC, sulforaphane analog.
NO donor; annexin A2 inhibitor.